(Q38148844)

29 August 2017

title

Systems biology, complexity, and the impact on antiepileptic drug discovery (English)

1 reference

29 August 2017

1 reference

Doru Georg Margineanu

series ordinal

1

1 reference

29 August 2017

publication date

3 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

38

1 reference

29 August 2017

page(s)

131-142

1 reference

29 August 2017

cites work

Milestones in epilepsy*.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The clinical concept of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

In search of models of pharmacoresistant epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Antiepileptic drug therapy: does mechanism of action matter?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Antiepileptogenic agents: how close are we?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Efficacy of new antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Identification of new epilepsy treatments: issues in preclinical methodology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

A new approach to decoding life: systems biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Systems biology: a brief overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Network biology: understanding the cell's functional organization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Genetics. Getting closer to the whole picture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Puzzling challenges in contemporary neuroscience: insights from complexity and emergence in epileptogenic circuits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The system epilepsies: a pathophysiological hypothesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Systems biology impact on antiepileptic drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The epilepsies: complex challenges needing complex solutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Multicomponent therapeutics for networked systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Network pharmacology: the next paradigm in drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Prospects for productivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Getting pharmaceutical R&D back on target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The productivity crisis in pharmaceutical R&D.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Diagnosing the decline in pharmaceutical R&D efficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The impact of systems approaches on biological problems in drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Target-based drug discovery: is something wrong?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Unveiling the role of network and systems biology in drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Network analyses in systems pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Can cell systems biology rescue drug discovery?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Cell signaling pathways as control modules: complexity for simplicity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The evolution of molecular biology into systems biology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Advanced computing for systems biology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

A network view of disease and compound screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Systems biology and new technologies enable predictive and preventative medicine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Systems biology and its application to the understanding of neurological diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

A measure for brain complexity: relating functional segregation and integration in the nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Complexity and the nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Learning about brain physiology and complexity from the study of the epilepsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

On the cellular and network bases of epileptic seizures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The Systems Biology Graphical Notation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Computer modelling of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Computational models of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Prediction by modeling that epilepsy may be caused by very small functional changes in ion channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Mechanisms of human inherited epilepsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Sodium channels and the neurobiology of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Mechanisms of drug resistance in epilepsy: relevance for antiepileptic drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Identification of pharmacoresistant epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Pharmacoresistant epilepsy: from pathogenesis to current and emerging therapies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

7 January 2021

Drug-resistant epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Early identification of refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The new antiepileptic drugs: scientific review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Drug resistance in brain diseases and the role of drug efflux transporters.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Molecular and cellular mechanisms of pharmacoresistance in epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Plasticity of antiepileptic drug targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Drug resistance in epilepsy: why is a simple explanation not enough?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Limited P-glycoprotein mediated efflux for anti-epileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Molecular and functional changes in voltage-dependent Na(+) channels following pilocarpine-induced status epilepticus in rat dentate granule cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Upregulation of a T-type Ca2+ channel causes a long-lasting modification of neuronal firing mode after status epilepticus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Seizure-induced plasticity of h channels in entorhinal cortical layer III pyramidal neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Gabapentin increases the hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Anticonvulsant pharmacology of voltage-gated Na+ channels in hippocampal neurons of control and chronically epileptic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Differential expression patterns of chloride transporters, Na+-K+-2Cl--cotransporter and K+-Cl--cotransporter, in epilepsy-associated malformations of cortical development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Altered distribution of KCC2 in cortical dysplasia in patients with intractable epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Increased NKCC1 expression in refractory human epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Immunological aspects of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Immunological aspects of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Epilepsy and the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Brain inflammation in epilepsy: experimental and clinical evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The pivotal role of immunity and inflammatory processes in epilepsy is increasingly recognized: introduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The role of inflammation in epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Astrocytes, from brain glue to communication elements: the revolution continues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Neocortical gliosis in temporal lobe epilepsy: gender-based differences.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Glutamate and astrocytes--key players in human mesial temporal lobe epilepsy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Loss of astrocytic domain organization in the epileptic brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

New facets of the neuropathology and molecular profile of human temporal lobe epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Astrocyte dysfunction in epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Functional changes in astroglial cells in epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Astrocyte dysfunction in neurological disorders: a molecular perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Astrocytic function and its alteration in the epileptic brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Can gap-junction blockade preferentially inhibit neuronal hypersynchrony vs. excitability?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Astrocytes in the hippocampus of patients with temporal lobe epilepsy display changes in potassium conductances.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The impact of astrocytic gap junctional coupling on potassium buffering in the hippocampus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The molecular basis of water transport in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Aquaporin-4 in the central nervous system: cellular and subcellular distribution and coexpression with KIR4.1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Loss of perivascular aquaporin 4 may underlie deficient water and K+ homeostasis in the human epileptogenic hippocampus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Gap junctions and connexin expression in the normal and pathological central nervous system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Upregulation in astrocytic connexin 43 gap junction levels may exacerbate generalized seizures in mesial temporal lobe epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Antiepileptic effect of gap-junction blockers in a rat model of refractory focal cortical epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Excitatory effects of gap junction blockers on cerebral cortex seizure-like activity in rats and mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Connexin36 gap junction blockade is ineffective at reducing seizure-like event activity in neocortical mouse slices.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Is connexin36 critical for GABAergic hypersynchronization in the hippocampus?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Properties of gap junction blockers and their behavioural, cognitive and electrophysiological effects: animal and human studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Tales of a Dirty Drug: Carbenoxolone, Gap Junctions, and Seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Gap junctions and epileptic seizures--two sides of the same coin?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Developing networks play a similar melody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Cation-chloride co-transporters in neuronal communication, development and trauma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Anomalous levels of Cl- transporters in the hippocampal subiculum from temporal lobe epilepsy patients make GABA excitatory.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Cellular and molecular mechanisms of epilepsy in the human brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Molecular neuropathology of temporal lobe epilepsy: complementary approaches in animal models and human disease tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Pathways to cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Mechanisms of action of antiepileptic drugs: the search for synergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Combining antiepileptic drugs--rational polytherapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Antiepileptic drug combinations--have newer agents altered clinical outcomes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

New horizons in the development of antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

From ion channels to complex networks: magic bullet versus magic shotgun approaches to anticonvulsant pharmacotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Antiepileptic drug discovery: does mechanism of action matter?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

New targets for drug action: is high selectivity always beneficial?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The brainweb: phase synchronization and large-scale integration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Emergent properties of CNS neuronal networks as targets for pharmacology: application to anticonvulsant drug action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

A human systems biology approach to discover new drug targets in epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Identifying targets for preventing epilepsy using systems biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Activity-dependent gene expression correlates with interictal spiking in human neocortical epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

An animal model to study the clinical significance of interictal spiking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Chemical biology and the limits of reductionism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Seizure freedom with more than one antiepileptic drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Established and emerging trends in computational drug discovery in the structural genomics era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The impact of network biology in pharmacology and toxicology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

A systems biology approach to identify effective cocktail drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The neurobiology of antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The anticonvulsants market

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

A systems level, functional genomics analysis of chronic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Is pharma running out of brainy ideas?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Why are antiepileptic drugs used for nonepileptic conditions?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

How to improve R&D productivity: the pharmaceutical industry's grand challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Traditional drug-discovery model ripe for reform

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Social engineering for virtual 'big science' in systems biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

How were new medicines discovered?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Modern phenotypic drug discovery is a viable, neoclassic pharma strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Multi-target drugs: the trend of drug research and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Toward standardized usage of the word serendipity in the historiography of psychopharmacology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

New antiepileptic drugs that are second generation to existing antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

Key factors in the discovery and development of new antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.08.029

10.1016/J.YEBEH.2013.08.029

7 January 2021

Identifiers

DOI

1 reference

29 August 2017

1 reference